Adelheid Wöhrer

List of Publications by Year
in descending order

150 papers	6,758 citations	76326 40 h-index	71685 76 g-index
154 all docs	154 docs citations	154 times ranked	10476 citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Protoporphyrin IX-Guided Neurosurgical Tumor Detection with Frequency-Domain Fluorescence Lifetime Imaging. Applied Sciences (Switzerland), 2022, 12, 1002.	2.5	1
2	The Digital Brain Tumour Atlas, an open histopathology resource. Scientific Data, 2022, 9, 55.	5.3	11
3	Enhanced expression of autophagy–related p62 without increased deposits of neurodegeneration–associated proteins in glioblastoma and surrounding tissue – An autopsy–based study. Brain Pathology, 2022, 32, e13058.	4.1	5
4	SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma. Cancers, 2022, 14, 1984.	3.7	2
5	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. Cancers, 2022, 14, 2163.	3.7	3
6	Improved accuracy of quantitative birefringence imaging by polarization sensitive <scp>OCT</scp> with simple noise correction and its application to neuroimaging. Journal of Biophotonics, 2021, 14, e202000323.	2.3	8
7	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. Cancers, 2021, 13, 566.	3.7	21
8	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. Cancers, 2021, 13, 603.	3.7	12
9	BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI. Neuro-Oncology Advances, 2021, 3, i1-i1.	0.7	0
10	LAG-3 expression in the inflammatory microenvironment of glioma. Journal of Neuro-Oncology, 2021, 152, 533-539.	2.9	22
11	How to predict the consistency and vascularity of meningiomas by MRI: an institutional experience. Neurological Research, 2021, 43, 693-699.	1.3	5
12	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	4.2	10
13	Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. BMC Cancer, 2021, 21, 754.	2.6	14
14	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. Journal of Personalized Medicine, 2021, 11, 624.	2.5	11
15	5-ALA in Suspected Low-Grade Gliomas: Current Role, Limitations, and New Approaches. Frontiers in Oncology, 2021, 11, 699301.	2.8	26
16	Fluorescence Lifetime Imaging and Spectroscopic Co-Validation for Protoporphyrin IX-Guided Tumor Visualization in Neurosurgery. Frontiers in Oncology, 2021, 11, 741303.	2.8	12
17	Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years. Cancers, 2021, 13, 6119.	3.7	6
18	Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy?. Neurosurgery, 2020, 86, 366-373.	1.1	29

#	Article	IF	Citations
19	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. Clinical Neuroradiology, 2020, 30, 599-605.	1.9	5
20	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. NeuroImage: Clinical, 2020, 28, 102433.	2.7	37
21	Macroscopic fluorescence-lifetime imaging of NADH and protoporphyrin IX improves the detection and grading of 5-aminolevulinic acid-stained brain tumors. Scientific Reports, 2020, 10, 20492.	3.3	24
22	Joint embedding: A scalable alignment to compare individuals in a connectivity space. NeuroImage, 2020, 222, 117232.	4.2	27
23	Distributed changes of the functional connectome in patients with glioblastoma. Scientific Reports, 2020, 10, 18312.	3.3	19
24	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. Journal of Neuro-Oncology, 2020, 148, 187-198.	2.9	25
25	Clinical presentation of young people (10â€"24Âyears old) with brain tumors: results from the international MOBI-Kids study. Journal of Neuro-Oncology, 2020, 147, 427-440.	2.9	20
26	Sex-Specific Differences in Primary CNS Lymphoma. Cancers, 2020, 12, 1593.	3.7	3
27	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. Cancers, 2020, 12, 1707.	3.7	18
28	Improved Diagnostic Imaging of Brain Tumors by Multimodal Microscopy and Deep Learning. Cancers, 2020, 12, 1806.	3.7	13
29	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. Npj Vaccines, 2020, 5, 5.	6.0	19
30	Retinal analysis of a mouse model of Alzheimerâ€™s disease with multicontrast optical coherence tomography. Neurophotonics, 2020, 7, 1.	3.3	22
31	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. Journal of Neurosurgery, 2020, 133, 1032-1043.	1.6	19
32	Ex-vivo Alzheimerâ€™s disease brain tissue investigation: a multiscale approach using 1060-nm swept source optical coherence tomography for a direct correlation to histology. Neurophotonics, 2020, 7, 035004.	3.3	1
33	NIMG-20. MULTI-HABITAT RADIOMICS UNRAVELS DISTINCT PHENOTYPIC SUBTYPES OF GLIOBLASTOMA WITH CLINICAL AND GENOMIC SIGNIFICANCE. Neuro-Oncology, 2020, 22, ii151-ii151.	1.2	0
34	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. Neuro-Oncology Advances, 2019, 1, i33-i33.	0.7	0
35	Intrameningioma Metastasis: A Wolf in Sheep's Clothing? Experience from a Series of 7 Cases. World Neurosurgery, 2019, 132, 169-172.	1.3	7
36	Comparison of Intensity- and Polarization-based Contrast in Amyloid-beta Plaques as Observed by Optical Coherence Tomography. Applied Sciences (Switzerland), 2019, 9, 2100.	2.5	4

#	Article	IF	Citations
37	Results of Phosphorus Magnetic Resonance Spectroscopy for Brain Metastases Correlate with Histopathologic Results. World Neurosurgery, 2019, 127, e172-e178.	1.3	4
38	Ex-vivo analysis of quantitative 5-ALA fluorescence intensity in diffusely infiltrating gliomas using a handheld spectroscopic probe: Correlation with histopathology, proliferation and microvascular density. Photodiagnosis and Photodynamic Therapy, 2019, 27, 354-361.	2.6	13
39	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta Oncológica, 2019, 58, 967-976.	1.8	8
40	RARE-49. SEX-SPECIFIC SURVIVAL ANALYSIS IDENTIFIES DIFFERENTIAL CLUSTERS OF PROGNOSTIC RELEVANCE IN PATIENTS WITH PRIMARY CNS LYMPHOMA. Neuro-Oncology, 2019, 21, vi232-vi232.	1.2	0
41	TMIC-09. MULTIMODAL VISIBLE LIGHT OPTICAL COHERENCE MICROSCOPY AND FLUORESCENCE IMAGING OF GLIOBLASTOMA REGIONAL SAMPLES. Neuro-Oncology, 2019, 21, vi248-vi249.	1.2	0
42	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
43	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. Radiotherapy and Oncology, 2019, 130, 139-148.	0.6	11
44	Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline. Journal of Neuroscience Methods, 2019, 311, 215-221.	2.5	12
45	Mitochondrial disorder mimicking rheumatoid disease. Zeitschrift Fur Rheumatologie, 2019, 78, 875-880.	1.0	8
46	Revealing brain pathologies with multimodal visible light optical coherence microscopy and fluorescence imaging. Journal of Biomedical Optics, 2019, 24, 1.	2.6	16
47	Polarization-sensitive imaging with simultaneous bright- and dark-field optical coherence tomography. Optics Letters, 2019, 44, 4040.	3.3	5
48	Combined visible light optical coherence microscopy and fluorescence imaging setup to investigate 5-aminolevulinic acid postive glioma samples. , 2019, , .		0
49	Multicentric malignant glioma with striking morphologic heterogeneity and early and extensive metastatic spread to the bone. , 2019, 38, 261-268.		0
50	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
51	MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals. Pituitary, 2018, 21, 266-273.	2.9	6
52	Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. Neuro-Oncology, 2018, 20, 411-419.	1.2	22
53	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 632-641.	1.2	33
54	Systematic histopathological analysis of different 5-aminolevulinic acid–induced fluorescence levels in newly diagnosed glioblastomas. Journal of Neurosurgery, 2018, 129, 341-353.	1.6	35

#	Article	IF	Citations
55	Glioma Survival Prediction with Combined Analysis of In Vivo ^{11}C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	5.0	94
56	COMP-12. TOWARDS BIG DATA IN DIGITAL NEUROPATHOLOGY WITH THE DIGITAL BRAIN TUMOR ATLAS. Neuro-Oncology, 2018, 20, vi66-vi66.	1.2	0
57	ACTR-32. 5-ALA FLUORESCENCE IS A POWERFUL MARKER FOR DETECTION OF UNEXPECTED GLIOBLASTOMA TISSUE DURING SURGERY OF RADIOLOGICALLY SUSPECTED LOW-GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi18-vi18.	1.2	0
58	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. Neuro-Oncology, 2018, 20, vi76-vi76.	1.2	0
59	Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathologica Communications, 2018, 6, 135.	5.2	37
60	Overview of cerebrospinal fluid cytology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 563-571.	1.8	36
61	Beyond backscattering: optical neuroimaging by BRAD. Biomedical Optics Express, 2018, 9, 2476.	2.9	25
62	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine, 2018, 24, 1611-1624.	30.7	229
63	5-ALA–induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. Neurosurgical Focus, 2018, 44, E7.	2.3	46
64	Assessment of pathological features in Alzheimer's disease brain tissue with a large field-of-view visible-light optical coherence microscope. Neurophotonics, 2018, 5, 1.	3.3	20
65	Investigating Pathological Features of Alzheimer's Disease in Human and Mouse Brain Tissue with Visible Light Optical Coherence Microscopy. , 2018, , .		0
66	Simultaneous Bright and Dark Field Optical Coherence Tomography Using Few-Mode Fiber Detection for Neuropathology Imaging. , 2018, , .		1
67	Imaging Brain Pathology in Alzheimer's Disease by Contrast-Enhanced Optical Coherence Tomography. , 2018, , .		0
68	Spatiotemporal evolution of a low-grade glioma with divergent oligodendroglial and astrocytic lineages. , 2018, 37, 82-84.		0
69	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. European Radiology, 2017, 27, 1556-1567.	4.5	26
70	Visible light spectral domain optical coherence microscopy system for ex vivo imaging. Proceedings of SPIE, 2017, , .	0.8	2
71	Visualization of neuritic plaques in Alzheimer's disease by polarization-sensitive optical coherence microscopy. Scientific Reports, 2017, 7, 43477.	3.3	41
72	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	1.2	213

#	Article	IF	Citations
73	MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary, 2017, 20, 643-653.	2.9	24
74	Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastoma. Scientific Reports, 2017, 7, 9674.	3.3	27
75	Spectroscopic imaging with spectral domain visible light optical coherence microscopy in Alzheimer's disease brain samples. Biomedical Optics Express, 2017, 8, 4007.	2.9	51
76	Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS). , 2017, 36, 5-14.		6
77	Visible light spectral domain optical coherence microscopy system for ex vivo brain imaging. , 2017, , .		1
78	Polarization-sensitive optical coherence microscopy of human brain samples. , 2017, , .		2
79	Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994¿¿2011. Cancer Epidemiology, 2016, 42, 72-81.	1.9	33
80	Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery, 2016, 94, 265-272.	1.5	27
81	Disseminated Intravascular Coagulation in Secondary Glioblastoma due to Excessive Intraoperative Bleeding: Case Report and Review of the Literature. World Neurosurgery, 2016, 90, 702.e7-702.e11.	1.3	2
82	Analysis of the surgical benefits of 5-ALA–induced fluorescence in intracranial meningiomas: experience in 204 meningiomas. Journal of Neurosurgery, 2016, 125, 1408-1419.	1.6	69
83	Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex. PLoS ONE, 2016, 11, e0157396.	2.5	69
84	Evolving evidence on tumor and germline genetic classification of gliomas: implications for etiology and survival studies. , 2016, 35, 31-37.		3
85	Clinical Neuropathology image 1-2015: Crystal-storing histiocytosis of the central nervous system. , 2015, 34, 4-5.		6
86	NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY. Neuro-Oncology, 2015, 17, v174.1-v174.	1.2	0
87	Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. Journal of Neurosurgery, 2015, 122, 803-811.	1.6	376
88	Haematopoietic stem cell transplantation for treatment of primary <scp>CNS</scp> lymphoma: single‐centre experience and literature review. European Journal of Haematology, 2015, 95, 75-82.	2.2	10
89	Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas. Neurosurgical Focus, 2015, 38, E4.	2.3	39
90	Molecular diagnostics: techniques and recommendations for 1p/19q assessment. CNS Oncology, 2015, 4, 295-306.	3.0	37

#	Article	IF	Citations
91	Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma. Oncology, 2015, 88, 173-179.	1.9	12
92	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	1.2	485
93	Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. , 2015, 34, 250-257.		42
94	The MOBI-Kids Study Protocol: Challenges in Assessing Childhood and Adolescent Exposure to Electromagnetic Fields from Wireless Telecommunication Technologies and Possible Association with Brain Tumor Risk. Frontiers in Public Health, 2014, 2, 124.	2.7	53
95	Letter to the Editor Complex-I defect with minimal manifestations. Archives of Medical Science, 2014, 1, 200-202.	0.9	0
96	Analysis of 5-aminolevulinic acid–induced fluorescence in 55 different spinal tumors. Neurosurgical Focus, 2014, 36, E11.	2.3	55
97	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	7.7	54
98	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. SpringerPlus, 2014, 3, 111.	1.2	21
99	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	1.4	10
100	Glioblastoma survival. Current Opinion in Neurology, 2014, 27, 666-674.	3.6	82
101	Presumed mitochondrial disease manifesting with recurrent syncopes. Journal of Cardiovascular Medicine, 2014, 15, 167-169.	1.5	0
102	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer, 2014, 83, 83-89.	2.0	63
103	<scp><i>BRAF</i></scp>‐Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <scp>CD</scp>34 Expression. Brain Pathology, 2014, 24, 221-229.	4.1	72
104	Atypical teratoid rhabdoid tumor: improved long‐term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992‐2012. Cancer Medicine, 2014, 3, 91-100.	2.8	99
105	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 2014, 128, 279-289.	7.7	191
106	Amplification and overexpression of <i><scp>CMET</scp></i> is a common event in brain metastases of non‐small cell lung cancer. Histopathology, 2014, 65, 684-692.	2.9	25
107	IgG4- related disease: an orphan disease with many faces. Orphanet Journal of Rare Diseases, 2014, 9, 110.	2.7	81
108	MRI features of Binswanger's disease predict prognosis and associated pathology. Annals of Clinical and Translational Neurology, 2014, 1, 813-821.	3.7	13

#	Article	IF	Citations
109	PD1 and PD-L1 expression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2011-2011.	1.6	4
110	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. Journal of Clinical Oncology, 2014, 32, 2012-2012.	1.6	1
111	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45
112	Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. , 2014, 33, 108-111.		21
113	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	2.9	14
114	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathologica, 2013, 126, 365-384.	7.7	264
115	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	7.7	177
116	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	2.4	48
117	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	3.3	66
118	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	2.0	59
119	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro-Oncology, 2013, 15, 112-121.	1.2	31
120	Frequent overexpression of ErbB – receptor family members in brain metastases of non‐small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	2.0	15
121	Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. Journal of Oncology Pharmacy Practice, 2013, 19, 170-174.	0.9	6
122	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	2.5	38
123	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. PLoS ONE, 2013, 8, e76988.	2.5	138
124	Innervated ectopic salivary gland associated with Rathke's cleft cyst clinically mimicking pituitary adenoma. , 2013, 32, 171-175.		9
125	Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. , 2013, 32, 269-285.		18
126	Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?. , 2013, 32, 5-8.		3

#	ARTICLE	IF	CITATIONS
127	Secondary gliosarcoma with massive invasion of meninges, skull base, and soft tissue, and systemic metastasis. , 2013, 32, 522-524.		5
128	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25
129	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	1.3	19
130	Novel crystalloid oligodendrogliopathy in hereditary spastic paraplegia. Acta Neuropathologica, 2012, 124, 583-591.	7.7	8
131	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Journal of Neuro-Oncology, 2012, 109, 323-330.	2.9	20
132	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	1.3	60
133	Trabectedin has promising antineoplastic activity in high†grade meningioma. Cancer, 2012, 118, 5038-5049.	4.1	57
134	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurgical Review, 2012, 35, 381-391.	2.4	86
135	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours †" a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology, 2012, 60, 885-894.	2.9	44
136	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magnetic Resonance Imaging, 2012, 30, 139-147.	1.8	39
137	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	7.7	204
138	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. Journal of Clinical Oncology, 2012, 30, 2053-2053.	1.6	0
139	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the*IDH1-R132H* Mutation in Diffuse Glioma Biopsy Specimens. Journal of Neuropathology and Experimental Neurology, 2011, 70, 715-723.	1.7	98
140	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. Acta Neuropathologica, 2011, 122, 787-790.	7.7	27
141	Current concepts and management of glioblastoma. Annals of Neurology, 2011, 70, 9-21.	5.3	380
142	Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 512-520.	1.9	38
143	5†Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer, 2010, 116, 1545-1552.	4.1	199
144	Incidence of atypical teratoid/rhabdoid tumors in children. Cancer, 2010, 116, 5725-5732.	4.1	126

#	Article	IF	Citations
145	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology, 2010, 42, 547-552.	0.6	42
146	Elevated blood markers 1 year before manifestation of malignant glioma. Neuro-Oncology, 2010, 12, 1004-1008.	1.2	16
147	Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of Neurosurgery, 2009, 111, 563-571.	1.6	34
148	O^6â€methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas. Cancer, 2009, 115, 1070-1080.	4.1	48
149	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. Journal of Neuro-Oncology, 2009, 95, 401-411.	2.9	157
150	Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biology and Therapy, 2008, 7, 1377-1385.	3.4	67